Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A Multi-Task Learning Approach for Identifying Prognostic Variables Across Multiple Historical Clinical Trials.

Created on 14 Oct 2026

Authors

Xueying Liu, Huijing Jiang, Jennie Zhang, Xinwei Deng

Published in

Statistics in medicine. Volume 45. Issue 23-24. Pages e70772.

Abstract

In clinical trials, it is critical to incorporate prognostic variables to improve precision for estimating treatment effects. Per FDA guidance, these prognostic variables need to be prospectively specified in the statistical analysis plan. Therefore, there is a great need to effectively identify prognostic variables from historical studies that are similar to the new study. In this work, we propose a multi-task learning method to identify prognostic variables from multiple related historical clinical trials. Specifically, a bi-level constraint variable selection (Bi-CVS) method is developed to identify both study-specific (within-study) and program-level (cross-study) prognostic variables. In addition, we develop an efficient algorithm for the Bi-CVS, tailored for clinical trial settings, and investigate its consistency property. The performance of the proposed method is evaluated through simulations for various endpoints, including continuous, binary, and time-to-event. A real clinical application is also presented to illustrate the proposed method.

PMID:
42867072
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement